Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CTI

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

J&J partner drive nets 15 new deals, and another NASH drug

Fosters new collaborations in treatment-resistant depression, infectious diseases and cancer

- PMLiVE

Pfizer/Opko’s long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change

- PMLiVE

Pfizer joins forces with IBM on immuno-oncology drug discovery

Engages the Watson supercomputer to accelerate research into new cancer therapies

Novartis building

Novartis adds oral eczema drug with Ziarco acquisition

Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

- PMLiVE

FDA green light for Pfizer’s eczema drug

Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube

IFPMA elects Pfizer’s Ian Read as president

Read succeeds Merck KGaA’s Dr Stefan Oschmann for a two-year term

- PMLiVE

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links